Grifols (GRFS) Total Liabilities (2009 - 2025)
Grifols' (GRFS) quarterly Total Liabilities came in at $14.1 billion in Q4 2025, up 3.06% YoY from $13.7 billion in Q4 2024, and up 3.06% on a QoQ basis from $13.7 billion in Q4 2024.
Grifols (GRFS) Total Liabilities (2009 - 2025) Analysis & Trends
Grifols (GRFS) has 17 years of Total Liabilities data on file, last reported at $14.1 billion in Q4 2025.
- Quarterly Total Liabilities rose 3.06% year-over-year to $14.1 billion in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $14.1 billion (up 3.06% YoY) and the FY2025 annual result came in at $14.1 billion, up 13584.86% from the prior year.
- Total Liabilities improved to $14.1 billion in Q4 2025, from $13.7 billion in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $14.5 billion in Q4 2023 to a low of $13.5 billion in Q4 2022.
- A 5-year average of $13.9 billion and a median of $13.7 billion in 2024 frame the typical range for Total Liabilities.
- Annual changes were most pronounced in 2021 — Total Liabilities soared 33.65% — and 2024, when it retreated 5.69%.
- Tracing GRFS's Total Liabilities over 5 years: stood at $13.6 billion in 2021, then decreased by 0.81% to $13.5 billion in 2022, then gained by 7.25% to $14.5 billion in 2023, then declined by 5.69% to $13.7 billion in 2024, then rose by 3.06% to $14.1 billion in 2025.
- The last three Total Liabilities figures came in at $14.1 billion (Q4 2025), $13.7 billion (Q4 2024), and $14.5 billion (Q4 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 116.09 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 135.12 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 129.80 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 80.09 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 65.46 Bn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 95.64 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 49.36 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | 115.64 Bn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | -59.79 Bn |
| 10 | Grifols | 5.45 Bn | 4.45 Bn | - | 14.10 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 14.10 Bn |
| Dec 31, 2024 | 13.68 Bn |
| Dec 31, 2023 | 14.50 Bn |
| Dec 31, 2022 | 13.52 Bn |
| Dec 31, 2021 | 13.63 Bn |
| Dec 31, 2020 | 10.20 Bn |
| Sep 30, 2020 | 18.28 Bn |
| Mar 31, 2020 | 17.55 Bn |
| Dec 31, 2019 | 9.63 Bn |
| Sep 30, 2019 | 15.62 Bn |
| Mar 31, 2019 | 15.22 Bn |
| Dec 31, 2018 | 8.88 Bn |
| Sep 30, 2018 | 13.70 Bn |
| Jun 30, 2018 | 8.91 Bn |
| Mar 31, 2018 | 16.45 Bn |
| Dec 31, 2017 | 8.58 Bn |
| Jun 30, 2017 | 8.28 Bn |
| Dec 31, 2016 | 6.91 Bn |
| Sep 30, 2016 | 6.74 Bn |
| Jun 30, 2016 | 6.92 Bn |